SCHEMBL1918976

SCHEMBL1918976

CCCc1nc2cc(C(=O)OC)cc(C)c2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
KDM4E B2RXH2 7/20 0.40
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
KMT2A Q03164 3/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
MEN1 O00255 2/20 0.39
ATM Q13315 1/20 0.39
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 2/20 0.38
RAB9A P51151 1/20 0.38
RXFP1 Q9HBX9 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707021 0.90 CA12 (0.42) MAPTPKMKDM4EKMT2AMEN1
SCHEMBL158113 0.85 APEX1 (0.41) KDM4EKMT2AMEN1ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL4437776 0.83 ALDH1A1 (0.41) KDM4EKMT2AMEN1ALDH1A1MAPK1
SCHEMBL1917751 0.81 ALDH1A1 (0.44) MAPTGAAKDM4EKMT2AMEN1
SCHEMBL6170453 0.80 KDM4E (0.45) MAPTGAAKDM4EPPARAKMT2A
SCHEMBL1918064 0.80 F9 (0.36) MAPTKDM4EKMT2ASMN1; SMN2HTT
SCHEMBL159894 0.79 ACACB (0.43) MAPTGAAPKMKDM4EPPARG
SCHEMBL1919439 0.78 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2MAPK1RAB9A
Hydrochloric Acid SCHEMBL14775596 0.78 ACACB (0.42) MAPTGAAPKMKDM4EPPARG
SCHEMBL8906504 0.77 L3MBTL1 (0.54) MAPTGAAPKMKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115572243-B Green preparation method of telmisartan key intermediate 湖南大学 2025-06-13 CN disclosed
CN-115572243-A Green preparation method of telmisartan key intermediate 湖南大学 2023-01-06 CN disclosed
CN-112251770-B Novel electrochemical preparation method of antihypertensive drug telmisartan intermediate 湖南大学 2021-07-27 CN disclosed
CN-111041516-B New preparation method of telmisartan intermediate of antihypertensive drug 湖南大学 2021-06-25 CN disclosed
CN-112251770-A Novel electrochemical preparation method of antihypertensive drug telmisartan intermediate 湖南大学 2021-01-22 CN disclosed
CN-111041516-A New preparation method of telmisartan intermediate of antihypertensive drug 湖南大学 2020-04-21 CN disclosed
EP-3081213-B1 TRICYCLIC COMPOUND KYOWA KIRIN CO LTD (JP) 2020-04-01 EP disclosed
US-9475805-B2 Tricyclic compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-10-25 US disclosed
EP-3081213-A1 TRICYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2016-10-19 EP disclosed
US-20150291587-A1 TRICYCLIC COMPOUND KYOWA KIRIN CO., LTD. (JP) 2015-10-15 US disclosed
US-8242151-B2 Tricyclic compounds KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-08-14 US disclosed
US-20110201640-A1 TRICYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-18 US disclosed
EP-2327690-A1 TRICYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2011-06-01 EP disclosed
CN-101921235-A Preparation method of telmisartan YICHANG CHANGJIANG PHARMACEUTICAL CO LTD 2010-12-22 CN disclosed
WO-2010081670-A2 PROCESS FOR THE PREPARATION OF BENZIMIDAZOLES LONZA LTD (CH) 2010-07-22 WO disclosed
US-20090176760-A1 TRICYCLIC COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-07-09 US disclosed
EP-1988091-A1 TRICYCLIC COMPOUNDS Kyowa Hakko Kogyo Co., Ltd (JP) 2008-11-05 EP disclosed
US-7012151-B1 Method for nitrating aniline derivatives BOEHRINGER INGELHEIM PHARMA KG (DE) 2006-03-14 US disclosed
EP-1173407-A1 METHOD FOR NITRATING ANILINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) 2002-01-23 EP disclosed
WO-2000063158-A1 METHOD FOR NITRATING ANILINE DERIVATIVES BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291587-A1 TRICYCLIC COMPOUND PPARA, PPARG, PPARD MAPT 4669/4885GAA 2399/4885PKM 1770/4885
US-20110201640-A1 TRICYCLIC COMPOUND PPARG, PPARA, PPARD MAPT 4554/4885GAA 2804/4885PKM 1903/4885
US-20090176760-A1 TRICYCLIC COMPOUNDS PPARG, PPARD, PPARA MAPT 4588/4885GAA 3391/4885PKM 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.